Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with stage III (not yet able to be removed by surgery) or stage IV endometrial cancer, confirmed through imaging
• People whose cancer has been confirmed by tissue testing to be a type called endometrial carcinoma
• People aged 18 to 75 years old
• People who are generally well enough to carry out daily activities with little or no limitation (this is measured by a standard medical scale called ECOG 0–1)
• People whose doctors consider them well enough to undergo surgery and radiation therapy
• People whose blood, liver, and kidney test results fall within the ranges required by the trial (confirm specific values with trial site)
• People who are able to attend follow-up appointments and are willing to follow the trial plan
• People who are willing and able to sign a consent form agreeing to the trial's requirements

Who may not be able to join:

• People who have an active, known, or suspected autoimmune disease, or a history of one — though some milder conditions may be exceptions, such as vitiligo, certain thyroid conditions managed with stable medication, type 1 diabetes managed with stable insulin, or childhood asthma that has fully resolved (confirm with trial site)
• People who have previously been treated with certain immune-based cancer therapies, including anti-PD-1, anti-PD-L1, or CTLA-4 drugs, or similar treatments that work through the immune system
• People who have a known allergy or sensitivity to any ingredient in the trial treatment
• People who have taken strong immune-suppressing medications (above a certain dose) in the two weeks before starting the trial — though some types such as creams, eye drops, nasal sprays, or inhalers may be permitted
• People who have taken herbal anti-cancer treatments or certain immune-modifying medicines in the two weeks before starting the trial
• People who currently have a serious active infection requiring treatment
• People who have had a serious infection in the four weeks before starting the trial, including infections that required hospitalisation, blood poisoning, or severe pneumonia
• People with untreated or poorly controlled hepatitis B, or active hepatitis C — people with stable, treated hepatitis B or cured hepatitis C may be considered (confirm with trial site)
• People with known active tuberculosis, or suspected active tuberculosis that has not been ruled out
• People with a weakened immune system or who test positive for HIV
• People with active or historical inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), or severe digestive problems that would affect the ability to take and absorb medication
• People with a known lung condition called interstitial lung disease that causes symptoms or could interfere with treatment monitoring
• People who have received a live or weakened live vaccine in the four weeks before starting the trial — standard inactivated flu vaccines are permitted
• People who have previously had a bone marrow transplant or solid organ transplant
• People who have had another primary cancer diagnosed within the past five years
• People who have had major surgery or serious physical trauma in the 28 days before starting the trial (certain implanted devices may be permitted — confirm with trial site)
• People with a history of a hole or abnormal opening (fistula) in the gastrointestinal tract or female reproductive organs
• People with certain uncontrolled heart or blood vessel conditions, significant recent bleeding, active bowel complications, uncontrolled fluid build-up around organs, or abnormal liver or kidney development (confirm specific details with trial site)
• People who are pregnant or breastfeeding, or women of childbearing age who are not willing to use contraception during the immunotherapy phase of the trial
• People who are currently participating in another interventional clinical trial — participation in observation-only studies is permitted
• People who, in the treating doctor's judgement, may be at increased risk from the trial treatment or are unlikely to be able to follow the trial requirements

Important: Always verify eligibility with the trial site directly before applying.